The acquisition of Avidity Biosciences (which traded under the ticker symbol RNA) by Novartis was finalized through a definitive merger agreement valuing the enterprise at approximately twelve billion dollars, with stockholders receiving seventy-two dollars per share in cash. This transaction represented a substantial premium over previous market valuations and positioned the buyout as one of the major pharmaceutical deals of the sector.